About Bystin
Bystin (BYSL) is a protein
from Homo sapiens identified by UniProt accession
Q13895, 437 residues long.
MolForge cross-references it against 0 known binders and
62 disease associations.
Target properties
| Protein name | Bystin |
|---|
| UniProt accession | Q13895 |
|---|
| Gene | BYSL |
|---|
| Organism | Homo sapiens |
|---|
| Length | 437 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (62)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.39
- reticulocyte count · score 0.28
- mean corpuscular volume · score 0.28
- mean reticulocyte volume · score 0.25
- erythrocyte count · score 0.24
- Red cell distribution width · score 0.18
- serum non-albumin protein measurement · score 0.18
- mean corpuscular hemoglobin concentration · score 0.16
- mean corpuscular hemoglobin · score 0.10
- monocyte percentage of leukocytes · score 0.08
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q13895-F1 | alphafold | PREDICTED | 77.45 | — |
Amino-acid sequence (437 residues)
MPKFKAARGV GGQEKHAPLA DQILAGNAVR AGVREKRRGR GTGEAEEEYV GPRLSRRILQ QARQQQEELE AEHGTGDKPA APRERTTRLG PRMPQDGSDD EDEEWPTLEK AATMTAAGHH AEVVVDPEDE RAIEMFMNKN PPARRTLADI IMEKLTEKQT EVETVMSEVS GFPMPQLDPR VLEVYRGVRE VLSKYRSGKL PKAFKIIPAL SNWEQILYVT EPEAWTAAAM YQATRIFASN LKERMAQRFY NLVLLPRVRD DVAEYKRLNF HLYMALKKAL FKPGAWFKGI LIPLCESGTC TLREAIIVGS IITKCSIPVL HSSAAMLKIA EMEYSGANSI FLRLLLDKKY ALPYRVLDAL VFHFLGFRTE KRELPVLWHQ CLLTLVQRYK ADLATDQKEA LLELLRLQPH PQLSPEIRRE LQSAVPRDVE DVPITVE
Explore Bystin with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets